Aaron Goldman
Operating Partner BroadOak Capital Partners
Seminars
Wednesday 29th July 2026
Investment Panel: How Funders Are Viewing the Opportunity in In Vivo Cell and Gene Therapies
3:30 pm
- How venture, government-backed and alternative funders are assessing the opportunity in in vivo cell and gene therapy, and where they see the strongest long-term value
- What is shaping funder conviction today, from early translational signals to platform potential and the pathway to clinical and commercial validation
- How funder perspectives on risk, timelines and capital deployment are evolving as in vivo approaches move closer to broader clinical and commercial reality
